Skip to content
rphrphrphV32V32V32

Drawing based on the description in the official product monograph. No photo yet.

“160 mg Tablets: grey orange, ovaloid-shaped, coated tablets with beveled edges, engraved with "rph" on one side and "V32" on the other side”

rph V32 pill

Pill with imprint rph V32 is gray & orange, oval and has been identified as Valsartan 160 mg. It is used for high blood pressure, heart failure and a weak heart. It is supplied by Teva Canada Limited.

Sold in Canada

Valsartan 160 mg

Brand
Teva-Valsartan
Imprint
rph V32
Strength
160 mg
Used for
High blood pressure, heart failure and a weak heart
Color
Gray, Orange
Shape
Oval
Form
Tablet
Manufacturer
Teva Canada Limited
Drug class
ARB (blood pressure medicine)
Sold in
Canada
DIN
02356678

Source: Health Canada's Drug Product Database and the official product monograph. Last checked .

Report a mistake

Please do not include personal health information. For questions about your medicine, ask a pharmacist.

All Valsartan pills and guides

What is Valsartan used for?

Valsartan is used for high blood pressure, heart failure, a weak heart and kidney disease from diabetes.

Medicine type
ARB (blood pressure medicine)
Official uses from the US prescribing label

1.1 Hypertension

Valsartan tablets are indicated for the treatment of hypertension, to lower blood pressure in adults and pediatric patients one year of age and older. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the class to which valsartan principally belongs. There are no controlled trials in hypertensive patients demonstrating risk reduction with valsartan tablets.

Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC).

Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly.

Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (e.g., patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal.

Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy.

Valsartan tablets may be used alone or in combination with other antihypertensive agents.

1.2 Heart Failure

Valsartan tablets are indicated to reduce the risk of hospitalization for heart failure in adult patients with heart failure (NYHA class II-IV). There is no evidence that valsartan tablets provides added benefits when it is used with an adequate dose of an angiotensin converting enzyme (ACE) inhibitor.

1.3 Post-Myocardial Infarction

In clinically stable adult patients with left ventricular failure or left ventricular dysfunction following myocardial infarction, valsartan tablet is indicated to reduce the risk of cardiovascular mortality.

From the FDA-approved label on DailyMed (published Sep 24, 2026).

Doctors sometimes prescribe a medicine for other reasons too. If you are not sure what yours is for, ask your pharmacist.

Is this your pill? Check every detail

  • Your pill shows rph V32. The parts can be split between the two sides, so turn the pill over and check both.
  • It is gray & orange, oval.
  • Its score line and coating match the details on this page.
  • It came from a pharmacy package that names the same drug.

Sold in Canada as Teva-Valsartan by Teva Canada Limited.

In Canada: prescription only.

Ingredients

Active: Valsartan

Pills that look similar but are different drugs

Same color and shape, different medicine. This is why the imprint matters.

Other Valsartan pills